QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology
VERAXA Biotech (NASDAQ: VRXA) was featured in a recent article highlighting how its collaboration with AI-focused research organization Ardigen could strengthen the company’s oncology pipeline as artificial intelligence plays an increasingly important role in drug discovery. By combining Ardigen’s expertise in AI, computational biology and bioinformatics with VERAXA’s proprietary BiTAC(R) platform, the companies aim to use AI to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while improving target validation and reducing development risks. VERAXA’s “AND-gated” approach, which activates therapies only when two cancer-associated targets are present on the same cell, may be particularly well suited to AI-driven analysis…